Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
INS-19 (Imunopharm) in Systemic Lupus Erythematosus: NCT06886919 Clinical Landscape Report 2026
15 October 2026
NCT06886919 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cemiplimab-RWLC in Metastatic melanoma: NCT06887088 Clinical Landscape Report 2026
15 October 2026
NCT06887088 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JY-231 in B-Cell Lymphoma: NCT06890065 Clinical Landscape Report 2026
15 October 2026
NCT06890065 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Prednisolone sodium metazoate in Diffuse Large B-Cell Lymphoma: NCT06890884 Clinical Landscape Report 2026
15 October 2026
NCT06890884 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Metastatic breast cancer: NCT06889688 Clinical Landscape Report 2026
15 October 2026
NCT06889688 clinical landscape for Metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TRS-005 in CD20 positive Diffuse Large B-Cell Lymphoma: NCT06886139 Clinical Landscape Report 2026
15 October 2026
NCT06886139 clinical landscape for CD20 positive Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Toripalimab in Metastatic Renal Cell Carcinoma: NCT06889649 Clinical Landscape Report 2026
15 October 2026
NCT06889649 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NY-ESO-1 TCR redirected autologous T cell product(Centre Hospitalier Universitaire Vaudois) in Sarcoma: NCT06889766 Clinical Landscape Report 2026
15 October 2026
NCT06889766 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mesenchymal Stem Cells(National Institute Of Blood And Marrow Transplant, Pakistan) in Dermatomyositis: NCT06888973 Clinical Landscape Report 2026
15 October 2026
NCT06888973 clinical landscape for Dermatomyositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CC-312 in Evans Syndrome: NCT06888960 Clinical Landscape Report 2026
15 October 2026
NCT06888960 clinical landscape for Evans Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JY-231 in Sjogren's Syndrome: NCT06887985 Clinical Landscape Report 2026
15 October 2026
NCT06887985 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MC150 in Systemic Lupus Erythematosus: NCT06892145 Clinical Landscape Report 2026
15 October 2026
NCT06892145 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.